PetIQ, Inc.

Equities

PETQ

US71639T1060

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
16.32 USD -1.27% Intraday chart for PetIQ, Inc. +1.81% -17.37%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
PetIQ, Inc. Announces Expansion of Minties Dental Treats Brand with Launch of New Dental Chew for Large-Sized Dogs CI
Transcript : PetIQ, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (PETQ) PETIQ Reports Q4 Revenue $219.9M, vs. Street Est of $189M MT
Petiq, Inc. Provides Sales Guidance for the First Quarter and Full Year of 2024 CI
PetIQ, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
PetIQ, Inc.'s New Sentry?? Portable Calming Diffuser Helps Calm Dogs and Cats During the Busy Holiday Season and Beyond CI
Tranche Update on PetIQ, Inc.'s Equity Buyback Plan announced on September 6, 2022. CI
PetIQ, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : PetIQ, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Petiq, Inc. Provides Earnings Guidance for the Full Year of 2023 CI
Earnings Flash (PETQ) PETIQ Reports Q3 EPS $0.42 MT
Earnings Flash (PETQ) PETIQ Posts Q3 Revenue $277M, vs. Street Est of $229.1M MT
Truist Securities Raises PetIQ's Price Target to $30 From $25, Keeps Buy Rating MT
PetIQ, Inc.(NasdaqGS:PETQ) added to S&P Health Care Services Select Industry Index CI
Lake Street Initiates PetIQ at Buy Rating With $28 Price Target MT
Tranche Update on PetIQ, Inc.'s Equity Buyback Plan announced on September 6, 2022. CI
Earnings Flash (PETQ) PETIQ Reports Q2 Revenue $314.5M, vs. Street Est of $273.8M MT
Earnings Flash (PETQ) PETIQ Reports Q2 EPS $0.46, vs. Street Est of $0.26 MT
Transcript : PetIQ, Inc., Q2 2023 Earnings Call, Aug 08, 2023
PetIQ, Inc. Provides Earnings Guidance for the Third Quarter of 2023 CI
PetIQ, Inc. Revises Earnings Guidance for the Full Year 2023 CI
PetIQ, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Petiq, Inc. Announces Termination of R. Michael Herrman, as Executive Vice President and Corporate Secretary CI
Tranche Update on PetIQ, Inc.'s Equity Buyback Plan announced on September 6, 2022. CI
Transcript : PetIQ, Inc., Q1 2023 Earnings Call, May 09, 2023
Chart PetIQ, Inc.
More charts
PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segment’s services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.32 USD
Average target price
29 USD
Spread / Average Target
+77.70%
Consensus

Quarterly revenue - Rate of surprise